These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37469246)

  • 121. ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
    Klempner SJ; Lee KW; Shitara K; Metges JP; Lonardi S; Ilson DH; Fazio N; Kim TY; Bai LY; Moran D; Yang J; Arozullah A; Park JW; Raizer JJ; Bang YJ; Shah MA
    Clin Cancer Res; 2023 Oct; 29(19):3882-3891. PubMed ID: 37490286
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity.
    Staropoli N; Salvino A; Falcone F; Farenza V; Costa M; Rossini G; Manti F; Crispino A; Riillo C; Ciliberto D; Arbitrio M; Tassone P; Tagliaferri P
    Front Oncol; 2023; 13():1145986. PubMed ID: 37492471
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community setting.
    Waterhouse D; Yong C; Frankart A; Brannman L; Mulrooney T; Robert N; Aguilar KM; Ndukum J; Cotarla I
    Future Oncol; 2023 Sep; 19(28):1905-1916. PubMed ID: 37497677
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.
    Colombo N; Lorusso D; Monk BJ; Slomovitz B; Hasegawa K; Nogueira-Rodrigues A; Zale M; Okpara CE; Barresi G; McKenzie J; Makker V
    Oncologist; 2024 Jan; 29(1):25-35. PubMed ID: 37523661
    [TBL] [Abstract][Full Text] [Related]  

  • 125.
    Ogimoto T; Ozasa H; Yoshida H; Nomizo T; Funazo T; Yoshida H; Hashimoto K; Hosoya K; Yamazoe M; Ajimizu H; Tsuji T; Sakamori Y; Kuninaga K; Morita S; Hirai T
    Oncol Lett; 2023 Aug; 26(2):364. PubMed ID: 37545625
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Ultrasound-mediated PLGA-PEI Nanobubbles Carrying STAT6 SiRNA Enhances NSCLC Treatment
    Shu H; Lv W; Ren ZJ; Li H; Dong T; Zhang Y; Nie F
    Curr Drug Deliv; 2024; 21(8):1114-1127. PubMed ID: 37491853
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Correction: Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial.
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37487668
    [No Abstract]   [Full Text] [Related]  

  • 128. Correction to "Clinical benefit of platinum doublet combination therapy in older adults with advanced non-small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan".
    Thorac Cancer; 2023 Sep; 14(25):2631. PubMed ID: 37485781
    [No Abstract]   [Full Text] [Related]  

  • 129. Cost-effectiveness of camrelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer.
    Liang X; Chen X; Li H; Li Y
    Immunotherapy; 2023 Oct; 15(14):1133-1142. PubMed ID: 37492009
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Efficacy of Osimertinib Continuation Plus Metronomic Oral Vinorelbine for EGFRmutant Advanced NSCLC Beyond Limited Progression on Osimertinib.
    Li M; Lin C; Lin J; Chen S; Weng L; He Z
    Anticancer Agents Med Chem; 2023; 23(19):2095-2101. PubMed ID: 37534792
    [TBL] [Abstract][Full Text] [Related]  

  • 131. A Th1-like CD4
    Yanagihara A; Yamasaki S; Hashimoto K; Taguchi R; Umesaki T; Imai H; Kaira K; Nitanda H; Sakaguchi H; Ishida H; Kobayashi K; Horimoto K; Kagamu H
    Cancer Res Commun; 2023 Jul; 3(7):1277-1285. PubMed ID: 37476074
    [TBL] [Abstract][Full Text] [Related]  

  • 132. Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell-derived organoids.
    Wu YH; Chao HS; Chiang CL; Luo YH; Chiu CH; Yen SH; Liu CY; Chiou JF; Burnouf T; Chen YJ; Wang PY; Chao TY; Hsu SM; Lu LS
    Thorac Cancer; 2023 Sep; 14(25):2591-2600. PubMed ID: 37474689
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Intraoperative lung ultrasound improves subcentimetric pulmonary nodule localization during VATS: Results of a retrospective analysis.
    Gambardella C; Messina G; Pica DG; Bove M; Capasso F; Mirra R; Natale G; D'Alba FP; Caputo A; Leonardi B; Puca MA; Giorgiano NM; Pirozzi M; Farese S; Zotta A; Miele F; Vicidomini G; Docimo L; Fiorelli A; Ciardiello F; Fasano M
    Thorac Cancer; 2023 Sep; 14(25):2558-2566. PubMed ID: 37470298
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Case Report: A case of hepatocellular carcinoma with aberrant right hepatic artery treated with transarterial chemoembolization and infusion chemotherapy separately to bilobar lesion combining with systemic therapies and sequential hepatectomy.
    Wei YG; Su H; Lv ZL; Liao XW; Zeng ZM; Jia YX; Huang HS; Shen XQ; Zhu GZ; Han CY; Ye XP; Peng T
    Front Oncol; 2023; 13():1165538. PubMed ID: 37469401
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Neutrophil estimation and prognosis analysis based on existing lung squamous cell carcinoma datasets: the development and validation of a prognosis prediction model.
    Wang Y; Li D; Li Q; Basnet A; Efird JT; Seki N
    Transl Lung Cancer Res; 2024 Aug; 13(8):2023-2037. PubMed ID: 39263021
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Relationship between the combination of platelet count and neutrophil-lymphocyte ratio and prognosis of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study.
    Kashimura S; Sato M; Inagaki T; Kin M; Manabe R; Kusumoto S; Horiike A; Tsunoda T; Kogo M
    Thorac Cancer; 2024 Oct; 15(28):2049-2060. PubMed ID: 39193939
    [TBL] [Abstract][Full Text] [Related]  

  • 137. Prognostic significance of pan-immune-inflammation value (PIV) in nasopharyngeal carcinoma patients.
    Zhang N; Hou T; Zhang S; Ling J; Jiang S; Xie Y; Liu X; Hu C; Feng Y
    Heliyon; 2024 Jan; 10(2):e24804. PubMed ID: 38312571
    [TBL] [Abstract][Full Text] [Related]  

  • 138. CRISPR-Cas System Is an Effective Tool for Identifying Drug Combinations That Provide Synergistic Therapeutic Potential in Cancers.
    Kim Y; Lee HM
    Cells; 2023 Nov; 12(22):. PubMed ID: 37998328
    [TBL] [Abstract][Full Text] [Related]  

  • 139. Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed.
    Imai H; Wasamoto S; Tsuda T; Nagai Y; Kishikawa T; Masubuchi K; Osaki T; Miura Y; Umeda Y; Ono A; Minemura H; Yamada Y; Nakagawa J; Kozu Y; Taniguchi H; Ohta H; Kasai T; Kaira K; Kagamu H
    Thorac Cancer; 2023 Sep; 14(25):2567-2578. PubMed ID: 37469246
    [TBL] [Abstract][Full Text] [Related]  

  • 140. Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer.
    Wasamoto S; Imai H; Tsuda T; Nagai Y; Kishikawa T; Ono A; Masubuchi K; Umeda Y; Yamada Y; Nakagawa J; Yui T; Taniguchi H; Kaira K; Kagamu H
    Intern Med; 2024 May; ():. PubMed ID: 38749728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.